The post Glenn Hughes Scores His Greatest Chart Debut On His Own appeared on BitcoinEthereumNews.com. Nearly 10 years after Resonate, Glenn Hughes scores a new career high as Chosen opens at No. 4 on the Official Rock and Metal Albums chart. NEW YORK, NEW YORK – APRIL 08: Glenn Hughes of Deep Purple speaks onstage during the 31st Annual Rock And Roll Hall Of Fame Induction Ceremony at Barclays Center on April 8, 2016 in New York City. (Photo by Mike Coppola/Getty Images) Getty Images Almost a decade after his last solo album Resonate arrived, Glenn Hughes returns with Chosen. The rock superstar’s fifteenth project under his own name debuts on multiple charts in the United Kingdom, where he remains a legend in his chosen field. Chosen opens inside loftiest tiers on multiple tallies and even gives Hughes his first solo win on one roster. Glenn Hughes Scores First Hit on One Chart Chosen debuts on the Official Albums Downloads chart at No. 60. Hughes scores his first solo win on the list of the bestselling full-lengths and EPs on download platforms like iTunes and Amazon in the U.K., as his latest project arrives. Glenn Hughes Reaches a New Peak Chosen earns its loftiest starting point on the Official Rock and Metal Albums chart, where it kicks off at No. 4. Hughes reaches a new all-time high as the set arrives and collects his second top 10. Resonate peaked at No. 6, earning Hughes his first top 10 bestseller almost 10 years back, while Music for the Divine only spent one frame at No. 33 nearly 20 years ago. Glenn Hughes on the Albums Charts Chosen also brings Hughes to new all-time peak positions on both the Official Albums Sales and Official Physical Albums charts. The set debuts at Nos. 25 and 26 on those tallies, respectively. Only Resonate had previously landed on those lists,… The post Glenn Hughes Scores His Greatest Chart Debut On His Own appeared on BitcoinEthereumNews.com. Nearly 10 years after Resonate, Glenn Hughes scores a new career high as Chosen opens at No. 4 on the Official Rock and Metal Albums chart. NEW YORK, NEW YORK – APRIL 08: Glenn Hughes of Deep Purple speaks onstage during the 31st Annual Rock And Roll Hall Of Fame Induction Ceremony at Barclays Center on April 8, 2016 in New York City. (Photo by Mike Coppola/Getty Images) Getty Images Almost a decade after his last solo album Resonate arrived, Glenn Hughes returns with Chosen. The rock superstar’s fifteenth project under his own name debuts on multiple charts in the United Kingdom, where he remains a legend in his chosen field. Chosen opens inside loftiest tiers on multiple tallies and even gives Hughes his first solo win on one roster. Glenn Hughes Scores First Hit on One Chart Chosen debuts on the Official Albums Downloads chart at No. 60. Hughes scores his first solo win on the list of the bestselling full-lengths and EPs on download platforms like iTunes and Amazon in the U.K., as his latest project arrives. Glenn Hughes Reaches a New Peak Chosen earns its loftiest starting point on the Official Rock and Metal Albums chart, where it kicks off at No. 4. Hughes reaches a new all-time high as the set arrives and collects his second top 10. Resonate peaked at No. 6, earning Hughes his first top 10 bestseller almost 10 years back, while Music for the Divine only spent one frame at No. 33 nearly 20 years ago. Glenn Hughes on the Albums Charts Chosen also brings Hughes to new all-time peak positions on both the Official Albums Sales and Official Physical Albums charts. The set debuts at Nos. 25 and 26 on those tallies, respectively. Only Resonate had previously landed on those lists,…

Glenn Hughes Scores His Greatest Chart Debut On His Own

Nearly 10 years after Resonate, Glenn Hughes scores a new career high as Chosen opens at No. 4 on the Official Rock and Metal Albums chart. NEW YORK, NEW YORK – APRIL 08: Glenn Hughes of Deep Purple speaks onstage during the 31st Annual Rock And Roll Hall Of Fame Induction Ceremony at Barclays Center on April 8, 2016 in New York City. (Photo by Mike Coppola/Getty Images)

Getty Images

Almost a decade after his last solo album Resonate arrived, Glenn Hughes returns with Chosen. The rock superstar’s fifteenth project under his own name debuts on multiple charts in the United Kingdom, where he remains a legend in his chosen field. Chosen opens inside loftiest tiers on multiple tallies and even gives Hughes his first solo win on one roster.

Glenn Hughes Scores First Hit on One Chart

Chosen debuts on the Official Albums Downloads chart at No. 60. Hughes scores his first solo win on the list of the bestselling full-lengths and EPs on download platforms like iTunes and Amazon in the U.K., as his latest project arrives.

Glenn Hughes Reaches a New Peak

Chosen earns its loftiest starting point on the Official Rock and Metal Albums chart, where it kicks off at No. 4. Hughes reaches a new all-time high as the set arrives and collects his second top 10.

Resonate peaked at No. 6, earning Hughes his first top 10 bestseller almost 10 years back, while Music for the Divine only spent one frame at No. 33 nearly 20 years ago.

Glenn Hughes on the Albums Charts

Chosen also brings Hughes to new all-time peak positions on both the Official Albums Sales and Official Physical Albums charts. The set debuts at Nos. 25 and 26 on those tallies, respectively. Only Resonate had previously landed on those lists, and it never reached even the upper half of those 100-spot rosters.

Source: https://www.forbes.com/sites/hughmcintyre/2025/09/17/glenn-hughes-scores-his-greatest-chart-debut-on-his-own/

Market Opportunity
Sidekick Logo
Sidekick Price(K)
$0.003298
$0.003298$0.003298
-15.26%
USD
Sidekick (K) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26